Page 183 - 2019_05-HaematologicaMondo-web

Efficacy of MM treatments
continued from the previous page
n/r {MPT vs. TD} 21.7 0.56 (0.4-0.79) n/r {VMP vs. MP}
15.2
n/r
23 0.8 (0.61-1.04) n/r {VMP vs. VTP} 32
n/r
14.7 1.12 (0.83-1.51)
(12-18.6) {VD vs. VTD} 15.4 0.89 (0.66-1.21) (12.6-24.2) {VTD vs. VMP} 17.3 1.11 (0.84-1.48)
(14.8-20.3) {VD vs. VMP} 35.3 0.58 (0.47-0.71)
n/r {VMPT-VT vs. VMP} 24.8
n/r
39 0.56 (0.39-0.79)
(26-53) {RD vs. D} 15
(8-23)
25.5 0.97 (0.83-1.12)
n/r {MPT vs. RD18} 20.7 1.43 (1.22-1.67) n/r {RD18 vs. RD} 21.2 1.39 (1.18-1.64) n/r {MPT vs. RD} 20 0.87 (0.72-1.04) (18-23) {MPR-R vs. MPT-T}
22
(19-27)
21 0.84 (0.64-1.09)
San Miguel 2008
VISTA
NCT00111319 Mateos 2014
GEM2005 NCT00443235 Niesvizky 2015
UPFRONT NCT00507416
Palumbo 2014
GIMEMA0305 NCT01063179 Zonder 2011
S0232
NCT00064038 Benboubkher 2014
FIRST/MM-020 NCT00689936
Zweegman 2016
HOVON-87
TTP
n/r
PFS
PFS
PFS
PFS
PFS
682
260
502
511
198
1623 Rd18 MPT 568
306
654
459
525
706
VMP 71
(57–90) MP 71
(48–91) VTP 73
(69–76) VMP 73
(68–77)
VD 75
(67-79) VTD 73
(66-77) VMP 72
(68-77) VMPT-VT 71
344
338
130 130 168 167 167
254 257 99 99
535
280
280
154 152
218
222 222
n/r 152 31 n/r 154 13 n/r 153 14 n/r 264 43
(39-52) 261 30
(25-39) 350 NR
356 18.1
(16.5-19.9)
56.4 60.1
43.1 60.1
43 72 63 72
49.8 44.3
51.5 41.3 53.1 43.4
NR 54 60.6 54 NR 45.4
NR 45.4
58.9 45.5 56.7 45.5 48.5 45.5
49 32.6
50 32.6
(68-75) VMP 71
RD n/r4 D n/r5
(68-75)
EUDRACT 2007-004007-34
Rd 73 (44–91)
73 541 (40–89)
73 547 (51–92)
MPT-T 72
(60-91) MPR-R 73
(60-87) MPT-T 76
(54-92)
MPR-R 77 (63-92)
MPR-R 74
(63-91)
CPR 73 (63-87)
Rd 73
(50-89) MPR-R 71
(65–87) MP 72
(65–91) MPR 71
Stewart 2015
ECOG E1A06 NCT00602641
Magarotto 2016
EMN01 NCT01093196
Palumbo 2012
MM-015 NCT00405756
Durie 2017ǁ SWOG S0777
NCT00644228 Mateos 2018
ALCYONE NCT02195479
PFS
PFS
PFS
PFS
PFS
52.6 40.7₸ (16-22) 47.7
(18-27) {MPT-T vs. MPR-R}
18.7
24 0.81 (0.63-1.03)
n/r {MPR-R vs. RD} 20 1.01 (0.9-1.13)
NR 39
NR 39 21 0.8(0.63-1.02) NR 39
n/r {CPR vs. RD}
(≥186) Rd n/r
(65–86)
{MPR-R vs. CPR} 0.49 (0.35-0.69) {MPR-R vs. MPR} 1.19 (0.94-1.5) {MP vs. MPR} 0.4 (0.29-0.54) {MPR-R vs. MP} 0.71 (0.56-0.91) {VRd vs. Rd}
0.50 (0.38-0.65) {DaraVMP vs. VMP}
56 53 52 53 54 53 52 54 38 56
NR 16.5
NR
VRd n/r
(≥187) DaraVMP 71
(40-93)
VMP 71
(50-91)
CI: confidence interval; N: number; itt: intention to treat; n/r: not reported; NR: not reached; PFS: progression-free survival; OS: overall survival; TTP: time to progression; EFS: event-free survival; ORR: overall response rate; RR: response rate, D: Dexamethasone; DI: Dexamethasone-Interferon alpha; M100: Melphalan 100; MD: Melphalan-Dexamethasone; MP: Melphalan- Prednisone; TD: Thalidomide-Dexamethasone; CTD: Cyclophosphamide-Thalidomide-Dexamethasone; CTD(a): Cyclophosphamide-Thalidomide-Dexamethasone (attenuated); Melphalan-Prednisone-Thalidomide/Melphalan-Prednisone-Thalidomide and Thalidomide maintenance (MPT/MPT-T); VD: Bortezomib-Dexamethasone; VTD: Bortezomib- Thalidomide-Dexamethasone; VMP: Bortezomib-Melphalan-Prednisone; VTP: Bortezomib-Thalidomide-Prednisone; VMPT-VT: Bortezomib-Melphalan-Prednisone-Thalidomide and Bortezomib-Thalidomide; CPR: Cyclophosphamide-Prednisone-Lenalidomide; Rd: Lenalidomide-Dexamethasone; Rd18: 18 cycles Lenalidomide-Dexamethasone; MPR: Melphalan- Prednisone-Lenalidomide; MPR-R: Melphalan-Prednisone-Lenalidomide and Lenalidomide maintenance;VRd: Bortezomib-Lenalidomide-Dexamethasone; DaraVMP: Daratumumab- Bortezomib-Melphalan-Prednisone; 140% ≥70 years 243% ≥70 years 339% ≥70 years.4 49% ≥65 years.5 47% ≥65 years.6 38% ≥65 years.7 48% ≥65 years Source HR: from published trial (MM-003,Ludwig2009,GIMEMA,MRC-MIX,GIMEMA0305,HOVON87,S0777,E1A06,ALCYONE,IFM-99/06,EMN01,FIRST),obtainedfromapreviouspatient-levelmeta-analysis5 (IFM- 01/01,NMSG,TMSG,HOVON49),from a previous NMA15 (Sacchi 2011) and data on file from investigators (Hungria 2016).Calculations were made using the published HR and P value (VISTA),Kaplan-Meier curves (IFM95/01 and the MM-15) and P-value and number of events (GEM2005,Upfront,s0232).Table 1 presents the extracted and calculated data.
haematologica | 2019; 104(5)
1029